$26.74
45.48% yesterday
Nasdaq, Nov 25, 10:18 pm CET
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$26.74
+24.37 1,028.27% 1M
+25.09 1,520.61% 6M
+23.84 821.59% YTD
+24.21 956.92% 1Y
-55.21 67.37% 3Y
-379.76 93.42% 5Y
-438.26 94.25% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+8.36 45.48%
ISIN
US30205M1018
Symbol
XCUR
Sector
Industry

Key metrics

Market capitalization $58.09m
Enterprise Value $63.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 127.76
P/S ratio (TTM) P/S ratio 116.18
P/B ratio (TTM) P/B ratio 37.60
Revenue growth (TTM) Revenue growth -97.70%
Revenue (TTM) Revenue $500.00k
EBIT (operating result TTM) EBIT $-5.00m
Free Cash Flow (TTM) Free Cash Flow $-2.88m
Cash position $340.00k
EPS (TTM) EPS $-2.26
Short interest 1.99%
Show more

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Exicure Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Exicure Inc:

Hold
100%

Financial data from Exicure Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.50 0.50
98% 98%
100%
- Direct Costs 0.81 0.81
51% 51%
162%
-0.31 -0.31
102% 102%
-62%
- Selling and Administrative Expenses 3.89 3.89
64% 64%
778%
- Research and Development Expense - -
-
-
-4.19 -4.19
155% 155%
-838%
- Depreciation and Amortization 0.81 0.81
51% 51%
162%
EBIT (Operating Income) EBIT -5 -5
183% 183%
-1,001%
Net Profit -4.01 -4.01
235% 235%
-802%

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Neutral
Business Wire
12 days ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Neutral
Business Wire
2 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 202...
Neutral
Business Wire
3 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open o...
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Paul Kang
Employees 6
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today